Is Baekje Shenzhou a foreign enterprise or a state-owned enterprise?

Baekje Shenzhou is a foreign company. Baekje Shenzhou refers to Baekje Shenzhou Biopharmaceutical Co., Ltd., which was established on 20 10 and headquartered in Beijing. The company always adheres to the concept of "patience, science and quality". In the initial stage, the company focused on improving R&D and innovation capabilities and strengthening cooperation with international pharmaceutical companies. During this period, four candidate drugs entered the clinical trial stage.

Baekje Shenzhou was listed on NASDAQ and HKEx on 20 16 and 20 18 respectively. In 20 17, the production bases in Suzhou and Guangzhou were completed, which provided a guarantee for commercial scale production, established commercial cooperation with Xinji, and enhanced the company's commercialization ability.

scope of business

R&D: Baekje Shenzhou focuses on the research and development of innovative drugs, especially drugs for treating cancer. The company has successfully developed a number of innovative drugs, and continuously invested in R&D resources to promote the clinical trials and listing of new drugs.

Production and commercialization: The company not only develops drugs, but also produces and commercializes drugs. A number of Baekje Shenzhou products have been approved for listing and sold in many countries and regions around the world, realizing the commercial operation of drugs.

Global Operation: Baekje Shenzhou's business covers many countries and regions, including China, the United States, Australia and Canada. The company conducts clinical trials, drug registration, production and sales around the world to meet the needs of patients in different countries and regions.

Enterprise honor

Enterprise ranking and market value: In 2020, Baekje Shenzhou was ranked as the top health private enterprise in Hurun China 100 12 with a market value of 83 billion yuan. In 2023, it ranked 48th in Hurun China Top 500 in 2022.

Product approval and certification: bruton's tyrosine kinase (BTK) inhibitor, Zbutenib, has been approved by the US Food and Drug Administration (FDA) to treat adult chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), and has also been approved in China. Council of Europe has approved first-line and second-line treatment for indications of non-small cell lung cancer (non-small cell lung cancer).

Employer Honor and Sustainable Development: In 2022, it was awarded as "the most sustainable employer in China in 2022".

Recognition of high-tech enterprises: it is recognized as "provincial high-tech enterprises" and "Top 500 high-tech enterprises in China in 2022".

Financial performance and market position

With the continuous listing and sales growth of products, the financial situation of Baekje Shenzhou continues to improve. For example, in the first quarter of 2024, the company's product revenue reached 5.325 billion yuan, an increase of 89.6%. Baekje Shenzhou has become an important participant in the global biomedical field, and its products have been recognized globally, and it continues to provide innovative treatment programs for patients.